
From: Zack Pemberton-Whiteley
Sent: 27 September 2017 09:35
To: Maria Pitan
Cc: David Coombs
Subject: RE: Initial scrutiny letter: Leukaemia (acute lymphoblastic, relapsed, adults) - inotuzumab ozogamicin [ID893]

Dear Maria,

I can confirm that we do not wish to respond to the initial scrutiny letter. However, we will be nominating representatives to attend the appeal hearing on the 3rd of November.

Kind Regards,

Zack

Zack Pemberton-Whiteley
Head of Campaigns and Advocacy

Office line: 01905 755977

Website: www.leukaemiacare.org.uk

Can you Spot Leukaemia?

Join us for Blood Cancer Awareness Month and help raise awareness of the signs and symptoms of leukaemia.
More info at www.leukaemiacare.org.uk/spot-leukaemia



Leukaemia CARE is registered as a charity in England and Wales (no.259483) and Scotland (no. SCO39207).
Registered office: One Birch Court, Blackpole East, Worcester, WR3 8SG.

From: Maria Pitan
Sent: 27 September 2017 09:29
To: Zack Pemberton-Whiteley
Cc: David Coombs
Subject: RE: Initial scrutiny letter: Leukaemia (acute lymphoblastic, relapsed, adults) - inotuzumab ozogamicin [ID893]

Dear Zack

The deadline for receiving a response to the initial scrutiny letter for the above appeal was yesterday, Tuesday 26 September. Please can you confirm that Leukaemia CARE do not wish to respond to any points for clarification in the letter?

Kind regards

Maria Pitan

Project Manager - Corporate Office
National Institute for Health and Care Excellence
10 Spring Gardens | London SW1A 2BU

Web: <http://www.nice.org.uk> Meetings held in public: <https://www.nice.org.uk/Get-Involved/Meetings-in-public>